Saturday 17 October 2026
Export TENX’s income statement to Excel — free account
Tenax Therapeutics, Inc.
TENX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 29.6% and free cash flow fell 125.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.36
0.15
−9.93%
Follow TENX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
15.58 | 14.57 | 14.52 | 15.07 |
Net Debt/EBITDA |
5.91 | 5.93 | 7.17 | 6.28 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.58 | 0.86 | 0.59 | 0.79 | |
Capex/Depreciation |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.23) | (0.34) | (0.21) | (0.28) | |
Cash per Share |
2.50 | 2.49 | 2.63 | 2.32 | |
Shareholders Equity per Share |
2.42 | 2.48 | 2.54 | 2.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.42 | 2.48 | 2.54 | 2.23 | |
Free Cash Flow |
(9.15) | (13.41) | (9.31) | (14.15) | |
Working Capital |
96.21 | 97.07 | 114.69 | 113.59 | |
Net Current Asset Value |
96.21 | 97.07 | 114.69 | 113.59 | |
| Other line items | |||||
Quick Ratio |
15.06 | 13.63 | 13.99 | 14.61 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.23) | (0.34) | (0.21) | (0.28) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
3.60 | 4.60 | 4.09 | 3.68 | |
Average Assets |
101.30 | 100.46 | 117.62 | 113.76 | |
Average Common Equity |
96.72 | 94.53 | 111.99 | 108.46 |
Columns are period end dates